-
2024-516099-13-00
5
2025-09-25
Severe Irritable Bowel Syndrome (IBS)
-
2024-511989-36-00
5
2025-09-24
Ewing Sarcoma
-
2024-513663-10-01
3
2025-09-17
Neoplasms
-
2024-516982-35-00
5
2025-09-11
Ovarian Cancer
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-514030-20-00
4
2025-08-29
colorectal cancer
-
2024-516772-15-00
1
2025-08-29
Metastatic Castration-Resistant Prostate Cancer
-
2024-518154-16-00
5
2025-08-27
non-small cell lung cancer
-
2024-519331-42-00
5
2025-08-22
pMMR endometrial carcinoma
-
2024-515875-36-00
4
2025-08-18
Advanced biliary tract cancer (BTC)
-
2024-515561-34-01
6
2025-08-04
Acute ischemic stroke with recent ingestion of direct oral anticoagula
-
2022-502983-19-00
4
2025-07-31
High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cance
-
2023-509630-19-00
5
2025-07-31
Esophageal Squamous Cell Carcinoma (ESCC)
-
2024-512583-57-00
5
2025-07-30
HER2-positive locally advanced or metastatic gastric or gastroesophage
-
2024-515349-41-00
4
2025-07-29
Metastatic Breast Cancer HR+, HER2-
-
2024-515787-31-00
5
2025-07-18
Patient with early triple-negative breast cancer (TNBC) achieving path
-
2024-518991-30-00
6
2025-07-17
kidney cancer
-
2024-512981-33-00
4
2025-07-09
Metastatic Colorectal Cancer
-
2024-516418-39-00
5
2025-07-09
Multiple Myeloma
-
2024-516834-36-00
5
2025-07-08
Locally recurrent unresectable or metastatic TNBC with tumors expressi
-
2024-518771-66-00
9
2025-07-01
Hepatoblastoma, Rhabdomyosarcoma
-
2024-519052-82-00
4
2025-06-30
pleural mesothelioma
-
2023-504831-42-00
5
2025-06-27
patient with colorectal cancer with hepatic metastasis
-
2024-516900-41-00
7
2025-06-24
Soft Tissue Sarcoma